Goldman Sachs
CTKB icon

Goldman Sachs’s Cytek Biosciences CTKB Stock Holding History

Goldman Sachs’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.6M Sell
2,167,515
-177,220
-8% -$757K ﹤0.01% 3272
2026
Q1 		$10.2M Buy
2,344,735
+554,821
+31% +$2.62M ﹤0.01% 3060
2025
Q4 		$9.04M Buy
1,789,914
+52,605
+3% +$244K ﹤0.01% 3191
2025
Q3 		$6.03M Buy
1,737,309
+720,752
+71% +$2.71M ﹤0.01% 3482
2025
Q2 		$3.46M Sell
1,016,557
-141,444
-12% -$471K ﹤0.01% 3753
2025
Q1 		$4.64M Sell
1,158,001
-183,751
-14% -$952K ﹤0.01% 3431
2024
Q4 		$8.71M Buy
1,341,752
+319,008
+31% +$1.9M ﹤0.01% 2937
2024
Q3 		$5.67M Sell
1,022,744
-334,507
-25% -$1.9M ﹤0.01% 3236
2024
Q2 		$7.57M Buy
1,357,251
+793,236
+141% +$4.76M ﹤0.01% 2772
2024
Q1 		$3.78M Buy
564,015
+1,236
+0.2% +$9.78K ﹤0.01% 3352
2023
Q4 		$5.13M Buy
562,779
+24,424
+5% +$154K ﹤0.01% 3133
2023
Q3 		$2.97M Sell
538,355
-30,040
-5% -$241K ﹤0.01% 3439
2023
Q2 		$4.85M Buy
568,395
+363,261
+177% +$3.26M ﹤0.01% 3132
2023
Q1 		$1.89M Sell
205,134
-156,988
-43% -$1.69M ﹤0.01% 3912
2022
Q4 		$3.7M Buy
362,122
+263,644
+268% +$3.54M ﹤0.01% 3446
2022
Q3 		$1.45M Buy
98,478
+23,586
+31% +$306K ﹤0.01% 4238
2022
Q2 		$803K Sell
74,892
-574,397
-88% -$5.72M ﹤0.01% 4777
2022
Q1 		$7M Buy
649,289
+589,229
+981% +$7.96M ﹤0.01% 3031
2021
Q4 		$980K Sell
60,060
-9,262
-13% -$194K ﹤0.01% 4852
2021
Q3 		$1.48M Buy
+69,322
New +$1.63M ﹤0.01% 4444

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Goldman Sachs's CTKB Position: Q2 2026 in Review

Goldman Sachs reduced its Cytek Biosciences (CTKB) stake by 7.6% in Q2 2026, selling an estimated $757K and leaving 2,167,515 shares worth $9.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

Goldman Sachs first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.2M in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Goldman Sachs held 2,167,515 shares of Cytek Biosciences worth $9.6M as of Q2 2026.
  • Goldman Sachs sold 177,220 Cytek Biosciences shares in Q2 2026, an estimated $757K.
  • Cytek Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3272 holding.
  • Goldman Sachs first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Goldman Sachs's Cytek Biosciences position peaked at $10.2M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.